By improving insulin sensitivity and reducing visceral fat, these medications help counteract some of the metabolic changes that occur when estrogen declines
Common side effects include gastrointestinal issues, which often resolve on their own within a few days
Many patients notice that sensations of feeling cold improve within the first few weeks or months, coinciding with the bodys adaptation to weight loss and reduced energy intake
52,53 In a phase 2, multi-center trial conducted at 45 centers, orforglipron at doses of 12 mg or greater showed significant reductions in HbA1c and bodyweight compared with placebo or dulaglutide
Description Semaglutide 10 mg GLP-1 Receptor Agonist for Metabolic Research Semaglutide is a long-acting glucagon-like peptide-1 (GLP-1) receptor agonist studied extensively in preclinical and clinical research for its effects on glycemic control, body weight, appetite regulation, and cardiometabolic markers
